On July 10, Dalmi Lee, a researcher at SK Securities, stated, "The company’s second-quarter performance peaked, and although sales growth may slow down entering the third-quarter off-season, solid results are still expected. Continuous launches of new COVID-19 diagnostic kits and increased demand due to the second wave of COVID-19 are expected to sustain growth until 2021." He set Seegene’s target price at 200,000 KRW.
Over the past five days, individual investors have net sold 254,153 shares of Seegene, while foreign investors and institutions have net bought 297,331 shares and net sold 31,324 shares, respectively.

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

